Latest news

• Novartis claims a rare win at ESMO for PI3K inhibitor class

  16%. Alpelisib was also fairly well tolerated in the 572-patient study, which involved patients whose disease had progressed after earlier treatment with an aromatase inhibitor with or without a ... 6 inhibitor, a newer drug group which includes

• Lilly gets EMA nod for Verzenio in breast cancer

  Eli Lilly has the approval it was looking for in Europe for CDK4/6 inhibitor Verzenio, allowing to challenge rivals from Pfizer and Novartis in breast cancer. ... women. It’s not all been plain sailing for Lilly’s CDK4/6 inhibitor programme however.

• Novartis considers filings for PI3K drug in breast cancer

  Novartis has positive phase III results in hand for its PI3K inhibitor alpelisib in advanced breast cancer patients, which it hopes will be enough to file for regulatory approvals. ... The two regimens were compared in patients whose cancer had

• Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

  It also backed three targeted cancer drugs: Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) as a combination for BRAF V600-positive melanoma; and Eli Lilly’s ... CDK4/6 inhibitor Verzenios (abemaciclib)

• FDA backs earlier use of Lilly’s breast cancer drug Verzenio

  Eli Lilly has picked up yet another FDA approval for CDK4/6 inhibitor Verzenio - its third in five months - as it tries to chase down Pfizer’s category-leading Ibrance. ... year and is predicted to become a $6bn product at peak by EvaluatePharma - as